The Predictive Role of E-cadherin and Androgen Receptor on In Vitro Chemosensitivity in Triple-negative Breast Cancer

被引:34
|
作者
Koo, Ja Seung [1 ]
Jung, Woohee [1 ]
Jeong, Joon [2 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
关键词
androgen receptor; breast cancer; chemosensitivity; E-cadherin; triple negative; CHEMOTHERAPY RESPONSE ASSAY; GENE-EXPRESSION; TUMOR CHEMOSENSITIVITY; ESTROGEN RECEPTORS; PROGNOSTIC-FACTORS; DUCTAL CARCINOMA; BASAL-LIKE; MARKERS; PROLIFERATION; SENSITIVITY;
D O I
10.1093/jjco/hyp065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The purpose of this study was to evaluate the impact of various pathologic and biologic factors in triple-negative breast cancer (TNBC) on chemotherapy response using in vitro ATP-based chemotherapy response assay (ATP-CRA). Methods: Forty-seven cases of TNBC were included. Immunohistochemical stains for androgen receptor (AR), p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin, Ki-67 and epidermal growth factor receptor were performed. In vitro ATP-CRA was used to analyze chemosensitivity for 5-fluorouracil (5-FU), docetaxel, doxorubicin, epirubicin, vinorelbine, gemcitabine, methotrexate (MTX), oxaliplatin and paclitaxel. Results: The results showed that all cytotoxic agents demonstrated the trend that E-cadherin-expressing cases had a higher cell death rate than E-cadherin-negative cases. Particularly, vinorelbine showed statistical significance (P = 0.004). Cases with AR expression showed higher cell death rates than those without in 5-FU and MTX (P = 0.012 and 0.014, respectively). Conclusions: E-cadherin and AR could be candidate predictive factors for chemotherapy response in TNBC. Further in vivo study is required to clarify their roles.
引用
收藏
页码:560 / 568
页数:9
相关论文
共 50 条
  • [41] The role of E-Cadherin expression in primary site of breast cancer
    Nora Karsten
    Thomas Kolben
    Sven Mahner
    Susanne Beyer
    Sarah Meister
    Christina Kuhn
    Elisa Schmoeckel
    Rachel Wuerstlein
    Nadia Harbeck
    Nina Ditsch
    Udo Jeschke
    Klaus Friese
    Theresa Maria Kolben
    Archives of Gynecology and Obstetrics, 2022, 305 : 913 - 920
  • [42] The role of E-Cadherin expression in primary site of breast cancer
    Karsten, Nora
    Kolben, Thomas
    Mahner, Sven
    Beyer, Susanne
    Meister, Sarah
    Kuhn, Christina
    Schmoeckel, Elisa
    Wuerstlein, Rachel
    Harbeck, Nadia
    Ditsch, Nina
    Jeschke, Udo
    Friese, Klaus
    Kolben, Theresa Maria
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 305 (04) : 913 - 920
  • [43] Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells
    Sakamoto, Takako
    Tanimoto, Keiji
    Eguchi, Hidetaka
    Sasaki, Shunta
    Tsuboi, Kouki
    Hayashi, Shin-ichi
    Ichihara, Sahoko
    BREAST CANCER, 2023, 30 (05) : 727 - 738
  • [44] Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
    A. Thakkar
    B. Wang
    M. Picon-Ruiz
    P. Buchwald
    Tan A. Ince
    Breast Cancer Research and Treatment, 2016, 157 : 77 - 90
  • [45] Triple-negative breast cancer: from classical clinicopathological features to androgen receptor profile
    Prutianu, Iulian
    Giusca, Simona Eliza
    Gafton, Bogdan
    Chifu, Mariana Bianca
    Terinte, Cristina
    Antonescu, Alexandra
    Popovici, Larisa
    Caruntu, Irina-Draga
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2024, 65 (02) : 209 - 216
  • [46] Androgen Receptor Expression in Triple-negative Breast Cancer and its Relation with Epidermal Growth Factor Receptor, CD 105, and Clinicopathological Parameters
    El Badawy, Nehal Ahmed
    El-Sheredy, Heba Gaber
    Fadali, Geylan Abd Elshafy
    Kazem, Amani Hussein
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (03) : 368 - 376
  • [47] Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
    Anestis, Aristomenis
    Karamouzis, Michalis V.
    Dalagiorgou, Georgia
    Papavassiliou, Athanasios G.
    CANCER TREATMENT REVIEWS, 2015, 41 (06) : 547 - 553
  • [48] Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro
    Garza-Morales, Rodolfo
    Gonzalez-Ramos, Roxana
    Chiba, Akiko
    Montes de Oca-Luna, Roberto
    McNally, Lacey R.
    McMasters, Kelly M.
    Gomez-Gutierrez, Jorge G.
    CANCERS, 2018, 10 (05)
  • [49] Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients
    Sindhu Govindan
    Mallikarjuna Siraganahalli Eswaraiah
    Chetana Basavaraj
    Manjula Adinarayan
    Satish Sankaran
    Manjiri Bakre
    BMC Cancer, 20
  • [50] Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients
    Govindan, Sindhu
    Eswaraiah, Mallikarjuna Siraganahalli
    Basavaraj, Chetana
    Adinarayan, Manjula
    Sankaran, Satish
    Bakre, Manjiri
    BMC CANCER, 2020, 20 (01)